Rational bases for the development of EGFR inhibitors for cancer treatment

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 7-8, 2007, Pages 1416-1431

  Bianco, Roberto ^a   Gelardi, Teresa ^a   Damiano, Vincenzo ^a   Ciardiello, Fortunato ^b   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cancer therapy; EGFR; Monoclonal antibodies; Target therapy; Tyrosine kinase inhibitors

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ARRY 334543; BMS 599626; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HR 3; LAPATINIB; MAB 806; MATUZUMAB; MDX 447; NIMOTUZUMAB; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB;

ANGIOGENESIS; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; DISEASE COURSE; GENE MUTATION; HUMAN; LIGAND BINDING; LUNG CANCER; METASTASIS; MONOTHERAPY; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMAL GROWTH FACTOR; HUMANS; MUTATION; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 34447097241     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.05.008     Document Type: Review

References (193)

1. Amit-Vazina M., Shishodia S., Harris D., Van Q., Wang M., Weber D., et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer 93 1 (2005) 70-80
2. Andl C.D., Mizushima T., Oyama K., Bowser M., Nakagawa H., and Rustgi A.K. EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 287 6 (2004) 1227-1237
3. AstraZeneca. Iressa (gefitinib) package insert (2004), AstraZeneca, Wilmington
4. Azemar M., Schmidt M., Arlt F., Kennel P., Brandt B., Papadimitriou A., et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int. J. Cancer 86 2 (2000) 269-275
5. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 Suppl. 4 (2002) 2-8
6. Baselga J., and Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs 60 Suppl. (2000) 33-40
7. Baselga J., Pfister D., Cooper M.R., Cohen R., Burtness B., Bos M., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18 5 (2000) 904-914
8. Batzer A.G., Rotin D., Urena J.M., Skolnik E.Y., and Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 14 8 (1994) 5192-5201
9. Beerli R.R., and Hynes N.E. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J. Biol. Chem. 271 11 (1996) 6071-6076
10. Benoit V.A., Chariot L., Delacroix V., Deregowski N., Jacobs M.P., and Merville V. Bours, Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression. Cancer Res. 64 8 (2004) 2684
11. Bianco R., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22 18 (2003) 2812-2822
12. Bleeker W.K., Lammerts van Bueren J.J., van Ojik H.H., Gerritsen A.F., Pluyter M., Houtkamp M., et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173 7 (2004) 4699-4707
13. Blencke S., Ullrich A., and Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278 17 (2003) 15435-15440
14. Borrell-Pages M., Rojo F., Albanell J., Baselga J., and Arribas J. TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J. 22 5 (2003) 1114-1124
15. Bromberg J. Stat proteins andoncogenesis. J. Clin. Invest. 109 9 (2002) 1139-1142
16. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 6 (1999) 857-868
17. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell. 12 3 (2003) 541-552
18. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96 8 (1999) 4240-4245
19. Carpenter G., and Cohen S. Epidermal growth factor. Annu. Rev. Biochem. 48 (1979) 193-216
20. Casado, E., Folprecht, G., Paz-Ares, L., Rojo, F., Köhne, C. H., Cortes-Funes, H., et al. (2004). A Phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). Proc. Am. Soc. Clin. Oncol., Abstract, 3543.
21. Chan S. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br. J. Cancer 91 8 (2004) 1420-1424
22. Chattopadhyay A., Vecchi M., Ji Q., Mernaugh R., and Carpenter G. The role of individual SH2 domains in mediating association of phospholipase C-g1 with the activated EGF receptor. J. Biol. Chem. 274 37 (1999) 26091-26097
23. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., and De Placido S. Antitumor activity of sequential treatment with tpotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5 (1999) 909-916
24. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6 5 (2000) 2053-2063
25. Ciardiello F., Caputo R., Troiani T., Bordello G., Kandimalla E.R., Agrawal S., et al. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int. J. Cancer 15 2 (2001) 172-178
26. Ciardiello F., Damiano V., Bianco R., Bianco C., Fontanini G., De Laurentiis M., et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. 88 23 (1996) 1770-1776
27. Citri A., Alroy I., Lavi S., Rubin C., Xu W., Grammatikakis N., et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy. EMBO J. 21 10 (2002) 2407-2417
28. Citri A., and Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell. Biol. 7 7 (2006) 505-516
29. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6 4 (2000) 443-446
30. Cochet O., Frelin C., Peyron J.F., and Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 18 4 (2005) 449-455
31. Cole, Alleva A.M., Reddy R.M., Maxhimer J.B., Zuo J., Schrump D.S., et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J. Thorac. Cardiovasc. Surg. 129 5 (2005) 1010-1017
32. Crombet T., Torres O., Rodriguez V., Menendez A., Stevenson A., Ramos M., et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study. Hybridoma 20 2 (2001) 131-136
33. Crombet-Ramos T., Figueredo J., Catala M., Menendez A., Stevenson A., Ramos M., et al. Treatment of high-grade astrocytic tumors with the humanized anti-EGF-R antibody h-R3 and radiotherapy. Proc. Am. Soc. Clin. Oncol., Abstract 2554 (2005)
34. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol. Immunother. 45 3/4 (1997) 210-215
35. Daaka Y. G proteins in cancer: The prostate cancer paradigm. Sci. STKE 216 (2004) re2
36. De Larco J.E., Reynolds R., Carlberg K., Engle C., and Todaro G.J. Sarcoma growth factor from mouse sarcoma virus-transformed cells. Purification by binding and elution from epidermal growth factor receptor-rich cells. J. Biol. Chem. 255 8 (1980) 3685-3690
37. Dolcet X., Llobet D., Pallares J., and Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 446 5 (2005) 475-482
38. Donato N.J., Yan D.H., Hung M.C., and Rosenblum M.G. Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. Cell Growth Differ. 4 5 (1993) 411-419
39. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307 5951 (1984) 521-527
40. Ekstrand A.J., Sugawa N., James C.D., and Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U. S. A. 89 10 (1992) 4309-4313
41. Ennis B.W., Lippman M.E., and Dickson R.B. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 9 5 (1991) 553-562
42. ERBITUX [package insert]. (2004). New York, NY. ImClone Systems Incorporated, and Princeton, NJ: Bristol-Myers Squibb Company.
43. Ferguson K.M. Active and inactive conformations of the epidermal growth factor receptor. Biochem. Soc. Trans. 32 5 (2004) 742-745
44. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., and Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell. 11 2 (2003) 507-517
45. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77 7 (1999) 527-543
46. Foon K.A., Yang X.D., Weiner L.M., Belldegrun A.S., Figlin R.A., Crawford J., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58 3 (2004) 984-990
47. Ford A.C., and Grandis J.R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25 1 (2003) 67-73
48. Friday B.B., and Adjei A.A. K-ras as a target for cancer therapy. Biochim. Biophys. Acta 1756 2 (2005) 127-144
49. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21 12 (2004) 2237-2246
50. Garland L.L., Pegram M., Song S., Mendelson D., Parker E., Martell R.E., et al. Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., Abstract 3152 (2005)
51. Garrison M.A., Tolcher A., McCreery H., Rowinsky E.K., Schott A., Mace J., et al. A Phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on Days 1, 8 and 15 every 28 days to patients with solid tumors. Proc. Am. Soc. Clin. Oncol., Abstract 289 (2001)
52. Gavin A.C., and Nebreda A.R. A MAP kinase docking site is required for phosphorylation and activation of p90(rsk)/MAPKAP kinase-1. Curr. Biol. 9 5 (1999) 281-284
53. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl. (2002) S81-S96
54. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INT ACT 1. J. Clin. Oncol. 22 5 (2004) 777-784
55. Gibson E.M., Henson E.S., Haney N., Villanueva J., and Gibson S.B. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res. 62 2 (2002) 488-496
56. Gibson S., Tu S., Oyer R., Anderson S.M., and Johnson G.L. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem. 274 25 (1999) 17612-17618
57. Gibson S., Tu S., Oyer R., Anderson S.M., and Johnson G.L. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem. 274 25 (1999) 17418-17612
58. Gille J., Swerlick R.A., and Caughman S.W. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and trans activation. EMBO J. 16 4 (1997) 750-759
59. Goldman C.K., Kim J., Wong W.L., King V., Brock T., and Gillespie G.Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell. 4 1 (1993) 121-133
60. Graus-Porta D., Beerli R.R., Daly J.M., and Hynes N.E. ErbB-2, the preferred eterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J. 16 7 (1997) 1647-1655
61. Gullick W.J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47 1 (1991) 87-98
62. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., and Carraway K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8132-8136
63. Hadari Y.R., Doody J.F., Wang Y., Patel S.N., Apblett R.L., Loizos N., et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. Proc. Am. Soc. Clin. Oncol., Abstract 234 (2004)
64. Harris R.C., Chung E., and Coffey R.J. EGF receptor ligands. Exp. Cell Res. 284 1 (2003) 2-13
65. Haslekas C., Breen K., Pedersen K.W., Johannessen L., Stang E., and Madshus I.H. The inhibitory effect of ErbB2 on EGF-induced formation of clathrin-coated pits correlates with retention of EGFR-ErbB2 oligomeric complexes at the plasma membrane. Mol. Biol. Cell 16 12 (2005) 5832-5842
66. Hecht J.R., Patnaik A., Malik I., Venook A., Berlin J., Croghan G., et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. Proc. Am. Soc. Clin. Oncol., Abstract 3511 (2004)
67. Henson E.S., and Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cell Signal 18 12 (2006) 2089-2097
68. Henson E.S., Gibson E.M., Villanueva J., Bristow N.A., Haney N., and Gibson S.B. Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbBl signaling pathway. J. Cell. Biochem. 89 6 (2003) 1177-1192
69. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J. Clin. Oncol. 22 5 (2004) 785-794
70. Herbst R.S., Heymach J.V., O'Reilly M.S., Onn A., and Ryan A.J. Expert Opin. Investig. Drugs 16 2 (2007) 239-249
71. Herbst R.S., and Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 94 5 (2002) 1593-1611
72. Hirsch F.R., Helfrich B., Franklin W.A., Varella-Garcia M., Chan D.C., and Bunn P.A. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clin. Breast Cancer 3 1 (2002) 12-16
73. Hoekstra R., Dumez H., van Oosterom A.T., Sizer K.C., Ravera C., Vaidyanathan S., et al. A Phase I and pharmacological study of PK1166, and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., Abstract 340 (2002)
74. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59 8 (1999) 1935-1940
75. Hughes D.P., Thomas D.G., Giordano T.J., Baker L.H., and McDonagh K.T. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 64 6 (2004) 2047-2053
76. Hynes N.E., and Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5 5 (2005) 341-354
77. ImClone Systems Inc., Bristol-Myers Squibb Company. ErbituxTM (cetuximab). (2004). US prescribing information. Princeton: ImClone Systems Inc.
78. Iwata K., Provoncha K., and Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc. Am. Soc. Clin. Oncol., Abstract 79 (2002)
79. Johns T.G., Stockert E., Ritter G., Jungbluth A.A., Huang H.J., Cavenee W.K., et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int. J. Cancer 988 3 (2002) 398-408
80. Johnson G.L., Dohlman H.G., and Graves L.M. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Curr. Opin. Chem. Biol. 9 3 (2005) 325-331
81. Jun T., Gjoerup O., and Roberts T.M. Tangled webs: Evidence of cross-talk between c-Raf-1 and Akt. Sci. STKE 1999 13 (1999) PE1
82. Kane L.P., Shapiro V.S., Stokoe D., and Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 9 11 (1999) 601-604
83. Kawaguchi Y., Kono K., Mimura K., Sugai H., Akaike H., and Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer (2006) (Epub.)
84. Kelly K., Gaspar L.E., Chansky K., Albain K.S., Crowley J., and Gandara D.R. Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing Phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc. Am. Assoc. Clin. Oncol., Abstract 1058 (2005)
85. Kim E.S., Khuri F.R., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. 13 6 (2001) 506-513
86. Kloth M.T., Laughlin K.K., Biscardi J.S., Boerner J.L., Parsons S.J., and Silva C.M. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J. Biol. Chem. 278 3 (2003) 1671-1679
87. Kuan C.T., Wikstrand C.J., and Bigner D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. End. Relat. Cancer 8 2 (2001) 83-96
88. Kumar R., Mandal M., Lipton A., Harvey H., and Thompson C.B. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res. 2 7 (1996) 1215-1219
89. Lax I., Burgess W.H., Bellot F., Ullrich A., Schlessinger J., and Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labelling. Mol. Cell. Biol. 8 4 (1988) 1831-1834
90. Lax I., Bellot F., Howk R., Ullrich A., Givol D., and Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J. 8 2 (1989) 421-427
91. Leaman D.W., Pisharody S., Flickinger T.W., Commane M.A., Schlessinger J., Kerr I.M., et al. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol. Cell. Biol. 16 1 (1996) 369-375
92. Lemmon M.A., and Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem. Sci. 19 11 (1994) 459-463
93. Lenferink A.E., De Roos A.D., Van Vugt M.J., Van de Poll M.L., and Van Zoelen E.J. The linear C-terminal regions of epidermal growth factor (EGF) and transforming growth factor-alpha bind to different epitopes on the human EGF receptor. Biochem. J. 336 1 (1998) 147-151
94. Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24 30 (2006) 4914-4921
95. Lin H., Chen C., Li X., and Chen B.D. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp. Cell Res. 272 2 (2002) 192-198
96. Liu Z., Li H., Derouet M., Filmus J., Lacasse E.C., Korneluk R.G., et al. ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: Epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J. Biol. Chem. 280 45 (2005) 37383-37392
97. Liu X., Yue P., Khuri F.R., and Sun S.Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64 15 (2004) 5078-5083
98. Longva K.E., Pedersen N.M., Haslekas C., Stang E., and Madshus I.H. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 116 3 (2005) 359-367
99. Lowenstein E.J., Daly R.J., Batzer A.G., Li W., Margolis B., Lammers R., et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signalling. Cell 70 3 (1992) 431-442
100. Luttrell L.M., Daaka Y., and Lefkowitz R.J. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11 2 (1999) 177-183
101. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 21 (2004) 2129-2139
102. Marais R., and Marshall C.J. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 27 (1996) 101-125
103. Massague J., and Pandiella A. Membrane-anchored growth factors. Annu. Rev. Biochem. 62 (1993) 515-541
104. McClellan M., Kievit P., Auersperg N., and Rodland K. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp. Cell Res. 246 2 (1999) 471-479
105. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 39 Suppl. C (2003) 1-16
106. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Rel. Cancer 8 1 (2001) 3-9
107. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33 4 (2006) 369-385
108. Meropol N.J., Berlin J., Hecht J.R., Croghan G.A., Patnaik A., Weiner L.M., et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., Abstract 1026 (2003)
109. Miknis G., Wallace E., and Lyssikatos J. ARRY-334543, a potent, orally active small molecule inhibitor of EGFR and ErbB-2. Proc. Am. Soc. Clin. Oncol., Abstract 3399 (2005)
110. Mishima K., Johns T.G., Luwor R.B., Scott A.M., Stockert E., Jungbluth A.A., et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61 14 (2001) 5349-5354
111. Morgillo F., Woo J.K., Kim E.S., Hong W.K., and Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 66 20 (2006) 10100-10111
112. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55 23 (1995) 5536-5539
113. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., and Cunningham A. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57 21 (1997) 4838-4848
114. Murphy L.O., Smith S., Chen R.H., Fingar D.C., and Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4 8 (2002) 556-564
115. Natale R.B., Skarin A., Maddox A.M., Hammond L.A., Thomas R., Gandara D.R., et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (Iressa) in IDEAL 2. Proc. Am. Soc. Clin. Oncol. Abstract 1167 (2002)
116. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl. 4 (2001) S9-S15
117. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 91 16 (1994) 7727-7731
118. Normanno N., Bianco C., De Luca A., Maiello M.R., and Salomon D.S. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr. Relat. Cancer 10 1 (2003) 1-21
119. Normanno N., Bianco C., De Luca A., and Salomon D.S. The role of EGF related peptides in tumor growth. Front. Biosci. 6 (2001) 685-707
120. Nyati M.K., Maheshwari D., Hanasoge S., Sreekumar A., Rynkiewicz S.D., Chinnaiyan A.M., et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res. 10 2 (2004) 691-700
121. O-charoenrat P., Rhys-Evans P., Modjtahedi H., and Eccles S.A. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin. Exp. Metastasis 18 2 (2000) 155-161
122. Ohgaki H. Genetic pathways to glioblastoma. Neuropathology 25 1 (2005) 1-7
123. OSI Pharmaceuticals. (2004). TarcevaTM (erlotinib) [package insert]. Melville: OSI Pharmaceuticals.
124. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
125. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 3 (2005) e73
126. Pao W., Miller V., Zakowski M., Doherty J., Politi K., and Sarkaria I. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 36 (2004) 13306-13311
127. Park Y.W., Younes M.N., Jasser S.A., Yigitbasi O.G., Zhou G., Bucana C.D., et al. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res. 11 5 (2005) 1963-1973
128. Patterson R.L., van Rossum D.B., Nikolaidis N., Gill D.L., and Snyder S.H. Phospholipase C-g: Diverse roles in receptor mediated calcium signaling. Trends Biochem. Sci. 30 12 (2005) 688-697
129. Peng D., Fan Z., Lu Y., DeBlasio T., Scher H., and Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56 16 (1996) 3666-3669
130. Perez-Torres M., Guix M., Gonzalez A., and Arteaga C.L. EGF receptor antibody downregulates mutant receptors and inhibits tumors expressing EGFR mutations. J. Biol. Chem. 281 December (52) (2006) 40183-40192
131. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5 2 (1999) 257-265
132. Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151 6 (1997) 1523-1530
133. Petrides P.E., Bock S., Bovens J., Hofmann R., and Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor β and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res. 50 13 (1990) 3934-3939
134. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291 2 (1999) 739-748
135. Prenzel N., et al. EGF receptor transactivation by G-protein coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402 6764 (1999) 884-888
136. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 6901 (2002) 934
137. Ravindranath N., Wion D., Brachet P., and Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J. Androl. 22 3 (2001) 432-443
138. Razandi M., Pedram A., Park S.T., and Levin E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278 4 (2003) 2701-2712
139. Riese D.J., Kim E.D., Elenius K., Buckley S., Klagsbrun M., Plowman D.D., et al. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J. Biol. Chem. 271 33 (1996) 20047-20052
140. Roskoski Jr. R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 319 1 (2004) 1-11
141. Ross H.J., Blumenschein G.R., Dowlati A., Aisner J., Rigas J.R., Stanislaus M., et al. Preliminary safety results of a Phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., Abstract 7099 (2005)
142. Rubin Grandis J., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 90 11 (1998) 824-832
143. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53 Suppl. 10 (1993) 2379-2385
144. Saito Y., Haendeler J., Hojo Y., Yamamoto K., and Berk B.C. Receptor heterodimerization: Essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor trans activation. Mol. Cell. Biol. 21 19 (2001) 6387-6394
145. Salazar R., Tabernero J., Rojo F., Jimenez E., Montaner I., Casado E., et al. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (Mab) EMD 72000 administered every three weeks (q3w). A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). Proc. Am. Soc. Clin. Oncol., Abstract 2002 (2004)
146. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19 3 (1995) 183-232
147. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18 1 (2006) 77-82
148. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22 14 (2004) 2954-2963
149. Scaltriti M., and Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin. Cancer Res. 12 18 (2006) 5268-5272
150. Scher H.I., Sarkis A., Reuter V., Cohen D., Netto G., Petrylak D., et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor a in the progression of prostatic neoplasms. Clin. Cancer Res. 1 5 (1995) 545-550
151. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 2 (2000) 211-225
152. Schlessinger J., and Lemmon M.A. Nuclear signaling by receptor tyrosine kinases: The first robin of spring. Cell 127 1 (2006) 45-48
153. Schonwasser D.C., Marais R.M., Marshall C.J., and Parker P.J. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol. 18 2 (1998) 790-798
154. Schwartz G., Dutcher J.P., Vogelzang N.J., Gollob J., Thompson J., Bukowski R.M., et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol., Abstract 91 (2002)
155. Sebastian S., Settleman J., Reshkin S.J., Azzariti A., Bellizzi A., and Paradiso A. The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochim. Biophys. Acta 1766 1 (2006) 120-139
156. She Q.B., Solit D., Basso A., and Moasser M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 9 12 (2003) 4340-4346
157. Shetty S., Gladden J.B., Henson E.S., Hu X., Villanueva J., Haney N., et al. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 7 5 (2002) 413-420
158. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97 5 (2005) 339-346
159. Shin D.M., Nemunaitis J., Zinner R.G., Donato N.J., Shin H.J.C., Myers J.N., et al. A Phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol., Abstract 324 (2001)
160. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96 12 (2004) 926-935
161. Simpson L., and Parsons R. PTEN: Life as a tumor suppressor. Exp. Cell Res. 264 1 (2001) 29-41
162. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 12 (2000) 4885-4892
163. Song G., Ouyang G., and Bao S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9 1 (2005) 59-71
164. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 5687 (2004) 1163-1167
165. Stoll S.W., Benedict M., Mitra R., Hiniker A., Elder J.T., and Nunez G. EGF receptor signaling inhibits keratinocyte apoptosis: Evidence for mediation by Bcl-XL. Oncogene 16 11 (1998) 1493-1499
166. Stover D.R., Becker M., Liebetanz J., and Lydon N.B. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J. Biol. Chem. 270 26 (1995) 15591-15597
167. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 16 (2005) 7052-7058
168. Sunpaweravong P., Sunpaweravong S., Puttawibul P., Mitarnun W., Zeng C., Baron A.E., et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 131 2 (2005) 111-119
169. Tabernero J., Rojo F., Jimenez E., Montaner I., Santome L., Guix M., et al. A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc. Am. Soc. Clin. Oncol., Abstract 770 (2003)
170. Takimoto R., and El-Deiry W.S. Wild-type p53 trans activates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19 14 (2000) 1735-1743
171. Tang X., Shigematsu H., Bekele B.N., Roth J.A., Minna J.D., Hong W.K., et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 65 17 (2005) 7568-7572
172. Tejpar S., Van Cutsem E., Gamelin E., Machover D., Soulie P., Ulusakarya A., et al. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol., Abstract 3579 (2004)
173. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 9496 (2005) 1527-1537
174. Toyoda H., Komurasaki T., Uchida D., and Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem. J. 326 1 (1997) 69-75
175. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-Molecular and clinical predictors of outcome. N. Engl. J. Med. 353 2 (2005) 133-144
176. US Food and Drug Administration. FDA public health advisory: New labeling and distribution program for gefitinib (Iressa) (2005), US Food and Drug Administration, DC
177. Vallbohmer D., Zhang W., Gordon M., Yang D.Y., Yun J., Press O.A., et al. Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 23 15 (2005) 3536-3544
178. Vanhoefer U., Tewes M., Rojo F., Dirsch O., Schleucher N., Rosen O., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22 (2004) 175-184
179. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo A role for altered tumor angiogenesis. Cancer Res. 61 13 (2001) 5090-5101
180. Voice J.K., Klemke R.L., Le A., and Jackson J.H. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 274 24 (1999) 17164-17170
181. Wang J.M., Chao J.R., Chen W., Kuo M.L., Yen J.J., and Yang-Yen H.F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 19 9 (1999) 6195-6206
182. Wang L.M., Kuo A., Alimandi M., Veri M.C., Lee C.C., Kapoor V., et al. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6809-6814
183. Waters S.B., Chen D., Kao A.W., Okada S., Holt K.H., and Pessin J.E. Insulin and epidermal growth factor receptors regulate distinct pools of Grb2-SOS in the control of Ras activation. J. Biol. Chem. 271 30 (1996) 18224-18230
184. Wells A. EGF receptor. Int. J. Biochem. Cell Biol. 31 6 (1999) 637-643
185. Yamazaki H., Kijima H., Ohnishi Y., Abe Y., Oshika Y., Tsuchida T., et al. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer Inst. 90 8 (1998) 581-587
186. Yang X.D., Jia X.C., Corvalan J.R., Wang P., and Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38 1 (2001) 17-23
187. Yang X.D., Jia X.C., Corvalan J., Wang P., Wu E., Zhang L., et al. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment. Proc. Am. Soc. Clin. Oncol., Abstract 183 (2000)
188. Yao M., Shuin T., Misaki H., and Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 48 23 (1988) 6753-6757
189. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 Suppl. 4 (2001) 3-8
190. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2 2 (2001) 127-137
191. Yokoi K., Thaker P.H., Yazici S., Rebhun R.R., Nam D.H., He J., et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. 65 9 (2005) 3716-3725
192. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., and Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3 11 (2001) 973-982
193. Zinner R.G., Donato N.J., Nemunaitis J.J., Cunningham C.C., Shin H.J., Zentgraf R.E., et al. Biomarker modulation in tumor an skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033. Proc. Am. Soc. Clin. Oncol., Abstract 58 (2002)